Advisor Group’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Advisor Group’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$20K	Hold	888	–	–	﹤0.01%	3957
2019 Q3	$18K	Hold	888	–	–	﹤0.01%	4013
2019 Q2	$19K	Buy	888 +188	+27%	+$3.91K	﹤0.01%	4004
2019 Q1	$15K	Buy	+700	New	+$14.6K	﹤0.01%	4131

Other funds holding FTXH

JAWM

J. Arnold Wealth Management Youngstown, Ohio $294M AUM 33.6% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SMFS

Squar Milner Financial Services Irvine, California $176M AUM 10.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Advisor Group's FTXH Position: Q4 2019 in Review

Advisor Group held its First Trust Nasdaq Pharmaceuticals ETF (FTXH) position steady in Q4 2019 at 888 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #3957.

Advisor Group first reported a position in FTXH in Q1 2019 and has held it in 4 quarters since. 11 funds tracked by Wall St. Rank hold FTXH as of Q4 2019.

Advisor Group held 888 shares of First Trust Nasdaq Pharmaceuticals ETF worth $20K as of Q4 2019.
Advisor Group left its First Trust Nasdaq Pharmaceuticals ETF share count unchanged in Q4 2019.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3957 holding.
Advisor Group first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2019 and has held it in 4 quarters since.
11 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.